Publikationen

Spektrenbibliotheken

  • Maurer/Meyer/Helfer/Weber "LC-HR-MS/MS Library of Drugs, Poisons, and
    Their Metabolites", 2018, Wiley

    Die in unserem Arbeitskreis entwickelte LC-HR-MS/MS-Spektrenbibliothek
    besteht aus mehr als 5000 Spektren von mehr als 2000 Arzneimittel, Drogen
    und Giften bzw. ihren Metaboliten. Der auf Metabolite basierende
    Screeningansatz, der mit dieser Bibliothek ermöglicht wird, in Kombination
    mit der hohen Sensitivität und Präzision der hochaufgelösten
    Tandem-Massenspektrometrie, kann einen bedeutenden Beitrag dazu leisten,
    falsch positive Ergebnisse zu minimieren.
 

Buchkapitel

  • Meyer, M.R., Toxicokinetics of NPS: Update 2017. Handb Exp Pharmacol, 2018. 252: p. 441-459.

Sonstige Veröffentlichungen

  • Wagmann, L. and Manier, S. K. and Meyer, M. R., Neuen Drogen auf der Spur mittels Chromatographie und MS, BIOspektrum, 2019.25(6): p. 637-639
  • Manier, S. K. and Keller, A. and Meyer, M. R., Methodenoptimierung in der Metabolomik, GIT Laborfachzeitschrift, 2019. 8: p. 40-42
  • Meyer, M.R. and H.H. Maurer, Goldstandard mit Fallstricken - Hochdruckflüssigchromatographie gekoppelt mit Tandem Massenspektrometrie. Trillium-Report, 2009. 7(2): p. 82-84.

Wissenschaftliche Artikel

2022

Wagmann, L. and M.R. Meyer, Reviewing toxicokinetics with a focus on metabolism of new psychoactive substances in the zebrafish (larvae) model. WIREs Forensic Science, 2022.

2021

Walle, N., et al., Comparison of in vitro and in vivo models for the elucidation of metabolic patterns of 7-azaindole-derived synthetic cannabinoids exemplified using cumyl-5F-P7AICA. Drug Test Anal, 2021. 13(1): p. 74-90.

Wagmann, L., et al., Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis. Molecules, 2021. 26(5).

Wagmann, L., S.K. Manier, and M.R. Meyer, Can the Intake of a Synthetic Tryptamine be Detected Only by Blood Plasma Analysis? A Clinical Toxicology Case Involving 4-HO-MET. J Anal Toxicol, 2021.

Wagmann, L., T.M. Gampfer, and M.R. Meyer, Recent trends in drugs of abuse metabolism studies for mass spectrometry-based analytical screening procedures. Anal Bioanal Chem, 2021. 413(22): p. 5551-5559.

Vollmer, A.C., L. Wagmann, and M.R. Meyer, Toxic plants-Detection of colchicine in a fast systematic clinical toxicology screening using liquid chromatography-mass spectrometry. Drug Test Anal, 2021.

Richter, M.J., et al., In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase Activity. Metabolites, 2021. 11(8).

Nordmeier, F., et al., Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans? Arch Toxicol, 2021. 95(12): p. 3681-3693.

Nordmeier, F., et al., Perimortem Distribution of U-47700, Tramadol and their Main Metabolites in pigs Following Intravenous Administration. J Anal Toxicol, 2021.

Nordmeier, F., et al., Are the N-demethylated metabolites of U-47700 more active than their parent compound? In vitro mu-opioid receptor activation of N-desmethyl-U-47700 and N,N-bisdesmethyl-U-47700. Drug Test Anal, 2021.

Manier, S.K., et al., Abuse of nutmeg seeds: Detectable by means of liquid chromatography-mass spectrometry techniques? Drug Test Anal, 2021. 13(7): p. 1440-1444.

Manier, S.K., et al., Studies on the In Vitro and In Vivo Metabolic Fate of the New Psychoactive Substance N-Ethyl-N-Propyltryptamine for Analytical Purposes. J Anal Toxicol, 2021. 45(2): p. 195-202.

Lauder, L., et al., Drug adherence and psychosocial characteristics of patients presenting with hypertensive urgency at the emergency department. J Hypertens, 2021. 39(8): p. 1697-1704.

Jacobs, C.M., L. Wagmann, and M.R. Meyer, Development, validation, and application of a quantitative volumetric absorptive microsampling-based method in finger prick blood by means of LC-HRMS/MS applicable for adherence monitoring of antipsychotics. Anal Bioanal Chem, 2021. 413(6): p. 1729-1737.

Jacobs, C.M., et al., Evaluation and analytical applicability of a novel volumetric absorptive microsampling strategy for adherence monitoring of antihypertensive drugs by means of LC-HRMS/MS. Anal Chim Acta, 2021. 1187: p. 339137.

Hemmer, S., L. Wagmann, and M.R. Meyer, Altered metabolic pathways elucidated via untargeted in vivo toxicometabolomics in rat urine and plasma samples collected after controlled application of a human equivalent amphetamine dose. Arch Toxicol, 2021. 95(10): p. 3223-3234.

Gampfer, T.M., et al., Cytotoxicity, metabolism, and isozyme mapping of the synthetic cannabinoids JWH-200, A-796260, and 5F-EMB-PINACA studied by means of in vitro systems. Arch Toxicol, 2021. 95(11): p. 3539-3557.

Belkacemi, A., et al., The TRPV2 channel mediates Ca2+ influx and the Delta9-THC-dependent decrease in osmotic fragility in red blood cells. Haematologica, 2021. 106(8): p. 2246-2250.

Bambauer, T.P., et al., Further development of a liquid chromatography-high-resolution mass spectrometry/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions. Drug Test Anal, 2021. 13(9): p. 1603-1613.

2020

Winter, M., et al., Transient Receptor Potential Vanilloid 6 (TRPV6) Proteins Control the Extracellular Matrix Structure of the Placental Labyrinth. Int J Mol Sci, 2020. 21(24).

Wagmann, L., et al., Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam. J Anal Toxicol, 2020.

Wagmann, L., et al., Toxicokinetics and Analytical Toxicology of Flualprazolam: Metabolic Fate, Isozyme Mapping, Human Plasma Concentration and Main Urinary Excretion Products. J Anal Toxicol, 2020. 44(6): p. 549-558.

Wagmann, L., et al., Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. Clin Chem Lab Med, 2020. 58(5): p. 664-672.

Wagmann, L., et al., How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings-A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish Larvae. Front Chem, 2020. 8: p. 539.

Valbuena Perez, J.V., et al., Altered glucocorticoid metabolism represents a feature of macroph-aging. Aging Cell, 2020. 19(6): p. e13156.

Strathmann, F.G., et al., Challenges of High-Resolution Mass Spectrometry For Detecting Designer Drugs. Clin Chem, 2020. 66(7): p. 868-874.

Park, Y.M., et al., Drug Administration Routes Impact the Metabolism of a Synthetic Cannabinoid in the Zebrafish Larvae Model. Molecules, 2020. 25(19).

Nordmeier, F., et al., Are pigs a suitable animal model for in vivo metabolism studies of new psychoactive substances? A comparison study using different in vitro/in vivo tools and U-47700 as model drug. Toxicol Lett, 2020. 329: p. 12-19.

Manier, S.K., et al., Toxicometabolomics of the new psychoactive substances alpha-PBP and alpha-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts. Arch Toxicol, 2020. 94(6): p. 2047-2059.

Manier, S.K., et al., Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver Microsomes. Metabolites, 2020. 11(1).

Manier, S.K., et al., Use of UPLC-HRMS/MS for In Vitro and In Vivo Metabolite Identification of Three Methylphenidate-derived New Psychoactive Substances. J Anal Toxicol, 2020. 44(2): p. 156-162.

Manier, S.K. and M.R. Meyer, Impact of the used solvent on the reconstitution efficiency of evaporated biosamples for untargeted metabolomics studies. Metabolomics, 2020. 16(3): p. 34.

Manier, S.K. and M.R. Meyer, Current Situation of the Metabolomics Techniques Used for the Metabolism Studies of New Psychoactive Substances. Ther Drug Monit, 2020. 42(1): p. 93-97.

Lauder, L., et al., Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. J Am Heart Assoc, 2020. 9(14): p. e014180.

Hemmer, S., et al., Comparison of Three Untargeted Data Processing Workflows for Evaluating LC-HRMS Metabolomics Data. Metabolites, 2020. 10(9).

Halberstadt, A.L., et al., Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology, 2020. 172: p. 107856.

Gampfer, T.M., et al., Toxicokinetic Studies and Analytical Toxicology of the New Synthetic Opioids Cyclopentanoyl-Fentanyl and Tetrahydrofuranoyl-Fentanyl. J Anal Toxicol, 2020. 44(5): p. 449-460.

Gampfer, T.M., et al., Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4 -fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine. Arch Toxicol, 2020. 94(6): p. 2009-2025.

Doerr, A.A., et al., Can A Recently Developed Pig Model Be Used for In Vivo Metabolism Studies of 7-Azaindole Derived Synthetic Cannabinoids? A Study Using 5F-MDMB-P7AICA. J Anal Toxicol, 2020.

Bambauer, T.P., et al., Analysis of alpha- and beta-amanitin in Human Plasma at Subnanogram per Milliliter Levels by Reversed Phase Ultra-High Performance Liquid Chromatography Coupled to Orbitrap Mass Spectrometry. Toxins (Basel), 2020. 12(11).

Bambauer, T.P., et al., Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MS. Talanta, 2020. 213: p. 120847.

2019

Wagmann, L., et al., In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem, 2019. 411(19): p. 4751-4763.

Wagmann, L., et al., Toxicokinetic studies of the four new psychoactive substances 4-chloroethcathinone, N-ethylnorpentylone, N-ethylhexedrone, and 4-fluoro-alpha-pyrrolidinohexiophenone. Forensic Toxicology, 2019. 38(1): p. 59-69.

Wagmann, L., et al., Phenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings. Drug Test Anal, 2019. 11(10): p. 1507-1521.

Wagmann, L., et al., Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Test Anal, 2019. 11(2): p. 318-324.

Schaefer, N., et al., Distribution of the (synthetic) cannabinoids JWH-210, RCS-4, as well as 9-tetrahydrocannabinol following pulmonary administration to pigs. Arch Toxicol, 2019. 93(8): p. 2211-2218.

Richter, L.H.J., H.H. Maurer, and M.R. Meyer, Metabolic fate of the new synthetic cannabinoid 7'N-5F-ADB in rat, human, and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry. Drug Test Anal, 2019. 11(2): p. 305-317.

Richter, L.H.J., et al., Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence. Anal Chim Acta, 2019. 1070: p. 69-79.

Richter, L.H.J., et al., Tools for studying the metabolism of new psychoactive substances for toxicological screening purposes - A comparative study using pooled human liver S9, HepaRG cells, and zebrafish larvae. Toxicol Lett, 2019. 305: p. 73-80.

Pettersson Bergstrand, M., et al., In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases. Drug Test Anal, 2019. 11(1): p. 45-50.

Nordmeier, F., et al., Studies on the in vitro and in vivo metabolism of the synthetic opioids U-51754, U-47931E, and methoxyacetylfentanyl using hyphenated high-resolution mass spectrometry. Sci Rep, 2019. 9(1): p. 13774.

Manier, S.K., et al., Untargeted metabolomics by high resolution mass spectrometry coupled to normal and reversed phase liquid chromatography as a tool to study the in vitro biotransformation of new psychoactive substances. Sci Rep, 2019. 9(1): p. 2741.

Manier, S.K., A. Keller, and M.R. Meyer, Automated optimization of XCMS parameters for improved peak picking of liquid chromatography-mass spectrometry data using the coefficient of variation and parameter sweeping for untargeted metabolomics. Drug Test Anal, 2019. 11(6): p. 752-761.

Gampfer, T.M., et al., Toxicokinetics and analytical toxicology of the abused opioid U-48800 - in vitro metabolism, metabolic stability, isozyme mapping, and plasma protein binding. Drug Test Anal, 2019. 11(10): p. 1572-1580.

2018

Wagmann, L., H.H. Maurer, and M.R. Meyer, Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse. Arch Toxicol, 2018. 92(9): p. 2875-2884.

Schaefer, N., et al., Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques? Biochem Pharmacol, 2018. 155: p. 403-418.

Pettersson Bergstrand, M., et al., Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. Drug Test Anal, 2018. 10(3): p. 496-506.

Michely, J.A., M.R. Meyer, and H.H. Maurer, Power of Orbitrap-based LC-high resolution-MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot cleavage in comparison to established LC-MS(n) or GC-MS procedures. Drug Test Anal, 2018. 10(1): p. 158-163.

Manier, S.K., et al., Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse. Drug Test Anal, 2018.

Hahn, D., et al., Antidepressant effects of direct-acting antivirals against hepatitis C virus-Results from a pilot study. Eur J Clin Invest, 2018. 48(12): p. e13024.

Caspar, A.T., et al., LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. Anal Bioanal Chem, 2018. 410(3): p. 897-912.

Caspar, A.T., et al., Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine. Talanta, 2018. 188: p. 111-123.

Caspar, A.T., M.R. Meyer, and H.H. Maurer, Blood plasma level determination using an automated LC-MS(n) screening system and electronically stored calibrations exemplified for 22 drugs and two active metabolites often requested in emergency toxicology. Drug Test Anal, 2018.

Caspar, A.T., M.R. Meyer, and H.H. Maurer, Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett, 2018. 285: p. 1-8.

Caspar, A.T., et al., Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry. Talanta, 2018. 176: p. 635-645.

Caspar, A.T., et al., Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MS(n) , and LC-HR-MS/MS. Drug Test Anal, 2018. 10(1): p. 184-195.

Blank, A., et al., The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. Clin Pharmacol Ther, 2018. 103(2): p. 341-348.

2017

Wagmann, L., H.H. Maurer, and M.R. Meyer, An easy and fast adenosine 5'-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5'-triphosphatase activity of the human breast cancer resistance protein ABCG2. J Chromatogr A, 2017. 1521: p. 123-130.

Wagmann, L., et al., In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. Toxicol Lett, 2017. 272: p. 84-93.

Richter, L.H.J., H.H. Maurer, and M.R. Meyer, New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-alpha-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine. Toxicol Lett, 2017. 280: p. 142-150.

Richter, L.H.J., et al., Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal, 2017. 143: p. 32-42.

Michely, J.A., M.R. Meyer, and H.H. Maurer, Paper Spray Ionization Coupled to High Resolution Tandem Mass Spectrometry for Comprehensive Urine Drug Testing in Comparison to Liquid Chromatography-Coupled Techniques after Urine Precipitation or Dried Urine Spot Workup. Anal Chem, 2017. 89(21): p. 11779-11786.

Michely, J.A., M.R. Meyer, and H.H. Maurer, Dried urine spots - A novel sampling technique for comprehensive LC-MS(n) drug screening. Anal Chim Acta, 2017. 982: p. 112-121.

Michely, J.A., et al., Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS(n), and LC-HR-MS/MS. Anal Bioanal Chem, 2017. 409(6): p. 1681-1695.

Mardal, M., et al., Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques. Drug Test Anal, 2017. 9(1): p. 106-114.

Mardal, M., et al., Microbial Biotransformation of Five Pyrrolidinophenone-type Psychoactive Substances in Wastewater and a Wastewater Isolated Pseudomonas putida Strain. Drug Test Anal, 2017.

Helfer, A.G., et al., Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma. Anal Chim Acta, 2017. 965: p. 83-95.

Helfer, A.G., et al., LC-HR-MS/MS standard urine screening approach: Pros and cons of automated on-line extraction by turbulent flow chromatography versus dilute-and-shoot and comparison with established urine precipitation. J Chromatogr B Analyt Technol Biomed Life Sci, 2017. 1043: p. 138-149.

Gracia-Lor, E., et al., Measuring biomarkers in wastewater as a new source of epidemiological information: Current state and future perspectives. Environ Int, 2017. 99: p. 131-150.

Castrignano, E., et al., A new approach towards biomarker selection in estimation of human exposure to chiral chemicals: a case study of mephedrone. Sci Rep, 2017. 7(1): p. 13009.

Caspar, A.T., et al., Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MS(n), and LC-HR-MS/MS approaches. J Pharm Biomed Anal, 2017. 134: p. 158-169.

Brandt, S.D., et al., Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. Drug Test Anal, 2017. 9(1): p. 115-126.

2016

Wagmann, L., M.R. Meyer, and H.H. Maurer, What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett, 2016. 258: p. 55-70.

Schaefer, N., et al., Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans? Drug Test Anal, 2016.

Richter, L.H., et al., Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem, 2016. 408(23): p. 6283-94.

Ott, C., et al., The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. J Hypertens, 2016. 34(12): p. 2475-2479.

Meyer, M.R. and H.H. Maurer, Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today? Anal Chim Acta, 2016. 927: p. 13-20.

Meyer, M.R., et al., Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem, 2016. 408(13): p. 3571-91.

Meyer, M.R., New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Arch Toxicol, 2016. 90(10): p. 2421-44.

Meyer, G.M., H.H. Maurer, and M.R. Meyer, Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. Bioanalysis, 2016. 8(5): p. 457-81.

Maurer, H.H. and M.R. Meyer, High-resolution mass spectrometry in toxicology: current status and future perspectives. Arch Toxicol, 2016. 90(9): p. 2161-2172.

Mardal, M., et al., 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. J Pharm Biomed Anal, 2016. 128: p. 485-495.

Mardal, M., et al., Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal, 2016. 8(10): p. 1039-1048.

Hoofnagle, A.N., et al., Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. Clin Chem, 2016. 62(1): p. 48-69.

Dinger, J., et al., Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett, 2016. 241: p. 82-94.

Dinger, J., M.R. Meyer, and H.H. Maurer, In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Arch Toxicol, 2016. 90(2): p. 305-18.

2015

Wink, C.S., et al., Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MS(n), and LC-high-resolution-MS(n). Anal Bioanal Chem, 2015. 407(3): p. 831-43.

Wink, C.S., et al., Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett, 2015. 238(3): p. 39-44.

Welter, J., et al., Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques. Anal Bioanal Chem, 2015. 407(5): p. 1371-88.

Welter, J., et al., Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques. Anal Bioanal Chem, 2015. 407(12): p. 3457-70.

Michely, J.A., et al., Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS. Anal Bioanal Chem, 2015. 407(25): p. 7831-42.

Meyer, M.R., et al., P-glycoprotein interactions of novel psychoactive substances - stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol, 2015. 94(3): p. 220-6.

Meyer, M.R., T. Vollerthun, and R. Hasselbach, Prevalence and distribution patterns of amphetamine and methamphetamine consumption in a federal state in southwestern Germany using wastewater analysis. Drug Alcohol Depend, 2015. 156: p. 311-4.

Meyer, M.R., A. Schutz, and H.H. Maurer, Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett, 2015. 232(1): p. 159-66.

Meyer, M.R., et al., First report on the pharmacokinetics of tramadol and O-desmethyltramadol in exhaled breath compared to plasma and oral fluid after a single oral dose. Biochem Pharmacol, 2015. 98(3): p. 502-10.

Meyer, M.R., et al., Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). J Mass Spectrom, 2015. 50(10): p. 1163-74.

Linicus, Y., et al., Witnessed drug intake before planned denervation--always harmless? Int J Cardiol, 2015. 179: p. 125-6.

Helfer, A.G., et al., Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal, 2015. 7(5): p. 368-75.

Helfer, A.G., et al., Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs. Anal Chim Acta, 2015. 891: p. 221-33.

Ewen, S., et al., Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol, 2015. 104(12): p. 1097-105.

Ewen, S., et al., Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. J Hypertens, 2015. 33(12): p. 2519-25.

Caspar, A.T., et al., Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS. Anal Bioanal Chem, 2015. 407(22): p. 6697-719.

Brandt, S.D., et al., Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. Rapid Commun Mass Spectrom, 2015. 29(7): p. 573-84.

2014

Wink, C.S., et al., Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS. Drug Test Anal, 2014. 6(10): p. 1038-48.

Welter, J., et al., Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn. Anal Bioanal Chem, 2014. 406(7): p. 1957-74.

Stolt, A.C., et al., Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology (Berl), 2014. 231(1): p. 13-25.

Remane, D., et al., Application of a UHPLC MS/MS-based multianalyte approach for screening and validated quantification of drugs in human blood plasma often requested in the context of brain death diagnosis. Ther Drug Monit, 2014. 36(2): p. 257-60.

Meyer, M.R., A. Robert, and H.H. Maurer, Toxicokinetics of novel psychoactive substances: characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. Toxicol Lett, 2014. 227(2): p. 124-8.

Meyer, M.R., L.H. Richter, and H.H. Maurer, Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. Anal Chim Acta, 2014. 822: p. 37-50.

Meyer, M.R. and H.H. Maurer, Forensic and clinical toxicology. Bioanalysis, 2014. 6(17): p. 2187.

Meyer, M.R., et al., The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.). Drug Test Anal, 2014. 6(7-8): p. 746-56.

Meyer, M.R., et al., Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry. Anal Bioanal Chem, 2014. 406(7): p. 1845-54.

Meyer, M.R., C. Lindauer, and H.H. Maurer, Dimethocaine, a synthetic cocaine derivative: studies on its in vitro metabolism catalyzed by P450s and NAT2. Toxicol Lett, 2014. 225(1): p. 139-46.

Meyer, M.R., A.G. Helfer, and H.H. Maurer, Current position of high-resolution MS for drug quantification in clinical & forensic toxicology. Bioanalysis, 2014. 6(17): p. 2275-84.

Meyer, M.R., et al., A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 beta-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal Bioanal Chem, 2014. 406(1): p. 225-37.

Meyer, M.R., Trends in analyzing emerging drugs of abuse--from seized samples to body samples. Anal Bioanal Chem, 2014. 406(25): p. 6105-10.

Mardal, M. and M.R. Meyer, Studies on the microbial biotransformation of the novel psychoactive substance methylenedioxypyrovalerone (MDPV) in wastewater by means of liquid chromatography-high resolution mass spectrometry/mass spectrometry. Sci Total Environ, 2014. 493: p. 588-95.

Helfer, A.G., et al., Direct analysis of the mushroom poisons alpha- and beta-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatography-high resolution-mass spectrometry/mass spectrometry. J Chromatogr A, 2014. 1325: p. 92-8.

Dinger, J., M.R. Meyer, and H.H. Maurer, Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett, 2014. 230(1): p. 28-35.

Dinger, J., M.R. Meyer, and H.H. Maurer, Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem, 2014. 406(18): p. 4453-64.

2013

Welter, J., et al., 2-methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem, 2013. 405(10): p. 3125-35.

Meyer, M.R., S. Schmitt, and H.H. Maurer, Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS. J Mass Spectrom, 2013. 48(2): p. 243-9.

Meyer, M.R., D. Prosser, and H.H. Maurer, Studies on the metabolism and detectability of the designer drug beta-naphyrone in rat urine using GC-MS and LC-HR-MS/MS. Drug Test Anal, 2013. 5(4): p. 259-65.

Meyer, M.R., T. Orschiedt, and H.H. Maurer, Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett, 2013. 217(2): p. 137-42.

Meyer, M.R., et al., Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem, 2013. 405(19): p. 6307-21.

Meyer, M.R., Do we need high-resolution MS in forensic and clinical toxicology? Bioanalysis, 2013. 5(10): p. 1161-3.

Meyer, G.M., et al., Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n). J Mass Spectrom, 2013. 48(1): p. 24-41.

Meyer, G.M., et al., Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. Biochem Pharmacol, 2013. 86(10): p. 1497-506.

Meyer, G.M., et al., Case report of accidental poisoning with the tranquilizer xylazine and the anesthetic ketamine confirmed by qualitative and quantitative toxicological analysis using GC-MS and LC-MS(n.). Drug Test Anal, 2013. 5(9-10): p. 785-9.

Dinger, J., M.R. Meyer, and H.H. Maurer, In Vitro Cytochrome P450 Inhibition Cocktail Assay-Part II: Development of an All-In-One Cocktail Approach: Dream or Reality? Therapeutic Drug Monitoring, 2013. 35(5): p. 687-688.

2012

Wissenbach, D.K., et al., Towards a universal LC-MS screening procedure - can an LIT LC-MS(n) screening approach and reference library be used on a quadrupole-LIT hybrid instrument? J Mass Spectrom, 2012. 47(1): p. 66-71.

Schwaninger, A.E., et al., Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA). Toxicol Lett, 2012. 212(1): p. 38-47.

Schwaninger, A.E., M.R. Meyer, and H.H. Maurer, Chiral drug analysis using mass spectrometric detection relevant to research and practice in clinical and forensic toxicology. J Chromatogr A, 2012. 1269: p. 122-35.

Schwaninger, A.E., et al., Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. Biochem Pharmacol, 2012. 83(1): p. 131-8.

Meyer, M.R., et al., New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. J Mass Spectrom, 2012. 47(2): p. 253-62.

Meyer, M.R. and F.T. Peters, Analytical toxicology of emerging drugs of abuse - an update. Ther Drug Monit, 2012. 34(6): p. 615-21.

Meyer, M.R. and H.H. Maurer, Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents. Anal Bioanal Chem, 2012. 402(1): p. 195-208.

Meyer, M.R. and H.H. Maurer, Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem, 2012. 403(5): p. 1221-31.

Meyer, M.R., et al., Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography-linear ion trap-mass spectrometry (LC-MS(n)). Anal Bioanal Chem, 2012. 402(3): p. 1249-55.

Meyer, M.R., Metabolism and Pharmacokinetics of Designer Cathinones. Biological Psychiatry, 2012. 71(8): p. 11s-11s.

Carow, F., et al., Objective assessment of nonadherence and unknown co-medication in hospitalized patients. Eur J Clin Pharmacol, 2012. 68(8): p. 1191-9.

2011

Wissenbach, D.K., et al., Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem, 2011. 400(1): p. 79-88.

Wissenbach, D.K., et al., Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept. Anal Bioanal Chem, 2011. 400(10): p. 3481-9.

Wink, C.S.D., et al., Metabolism of the lefetamine-derived designer drugs NEDPA and NPDPA using GC-MS, LC-MSn, and LC-HRMS and its detectability in urine. Therapeutic Drug Monitoring, 2011. 33(4): p. 470-470.

Schwaninger, A.E., et al., Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicol Lett, 2011. 202(2): p. 120-8.

Schwaninger, A.E., M.R. Meyer, and H.H. Maurer, Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine metabolites 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach. Drug Metab Dispos, 2011. 39(11): p. 1998-2002.

Schwaninger, A.E., et al., Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. J Mass Spectrom, 2011. 46(7): p. 603-14.

Schwaninger, A.E., et al., Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. Clin Chem, 2011. 57(12): p. 1748-56.

Remane, D., et al., Full validation and application of an ultra high performance liquid chromatographic-tandem mass spectrometric procedure for target screening and quantification of 34 antidepressants in human blood plasma as part of a comprehensive multi-analyte approach. Anal Bioanal Chem, 2011. 400(7): p. 2093-107.

Remane, D., et al., Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs. Anal Bioanal Chem, 2011. 401(4): p. 1341-52.

Philipp, A.A., et al., Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal Bioanal Chem, 2011. 400(1): p. 127-35.

Peters, F.T. and M.R. Meyer, In vitro approaches to studying the metabolism of new psychoactive compounds. Drug Test Anal, 2011. 3(7-8): p. 483-95.

Meyer, M.R., et al., Development, validation, and application of a fast and simple GC-MS method for determination of some therapeutic drugs relevant in emergency toxicology. Ther Drug Monit, 2011. 33(5): p. 649-53.

Meyer, M.R., A.A. Weber, and H.H. Maurer, A validated GC-MS procedure for fast, simple, and cost-effective quantification of glycols and GHB in human plasma and their identification in urine and plasma developed for emergency toxicology. Anal Bioanal Chem, 2011. 400(2): p. 411-4.

Meyer, M.R., et al., Development and validation of an LC-MS/MS approach for quantification of drugs in human plasma requested in context of brain death diagnosis. Therapeutic Drug Monitoring, 2011. 33(4): p. 470-470.

Meyer, M.R. and H.H. Maurer, Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics, 2011. 12(2): p. 215-33.

Derungs, A., et al., Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol (Phila), 2011. 49(7): p. 691-3.

2010

Zollner, A., et al., Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. Bioanalysis, 2010. 2(7): p. 1277-90.

Stuttmann, R., et al., The breast feeding mother and xenon anaesthesia: four case reports. Breast feeding and xenon anaesthesia. BMC Anesthesiol, 2010. 10: p. 1.

Schwaninger, A.E., M.R. Meyer, and H.H. Maurer, Gas chromatography-mass spectrometry detection of a norfluoxetine artifact in hydrolyzed urine samples may falsely indicate tranylcypromine ingestion. J Anal Toxicol, 2010. 34(1): p. 45-8.

Remane, D., et al., Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures. Rapid Commun Mass Spectrom, 2010. 24(7): p. 859-67.

Remane, D., et al., Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization. Rapid Commun Mass Spectrom, 2010. 24(21): p. 3103-8.

Remane, D., et al., Fast and simple procedure for liquid-liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma. Anal Bioanal Chem, 2010. 397(6): p. 2303-14.

Meyer, M.R., et al., Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem, 2010. 397(3): p. 1225-33.

Meyer, M.R., F.T. Peters, and H.H. Maurer, Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. Clin Chem, 2010. 56(4): p. 575-84.

Meyer, M.R. and H.H. Maurer, Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab, 2010. 11(5): p. 468-82.

Meyer, M.R., et al., Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom, 2010. 45(12): p. 1426-42.

2009

Schwaninger, A.E., et al., The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metab Dispos, 2009. 37(11): p. 2212-20.

Schwaninger, A.E., et al., MDMA Phase II Metabolites R- and S-4-Hydroxy-3-methoxy-methamphetamine-O- glucuronides: Synthesis Using Rat Liver Microsomes, Isolation and Clean-up. Therapeutic Drug Monitoring, 2009. 31(5): p. 606-607.

Sauer, C., et al., Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochem Pharmacol, 2009. 77(3): p. 444-50.

Sauer, C., et al., New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom, 2009. 44(6): p. 952-64.

Meyer, M.R., F.T. Peters, and H.H. Maurer, The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers. Drug Metab Dispos, 2009. 37(6): p. 1152-6.

Meyer, M.R., F.T. Peters, and H.H. Maurer, Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem Pharmacol, 2009. 77(11): p. 1725-34.

Meyer, M.R., F.T. Peters, and H.H. Maurer, Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. Toxicol Lett, 2009. 190(1): p. 54-60.

Meyer, M.R. and H.H. Maurer, Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem Res Toxicol, 2009. 22(6): p. 1205-11.

Jung, J., et al., Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. J Mass Spectrom, 2009. 44(10): p. 1423-33.

2008

Sauer, C., et al., Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine. Chem Res Toxicol, 2008. 21(10): p. 1949-55.

Peters, F.T., et al., Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone. Drug Metab Dispos, 2008. 36(1): p. 163-8.

Meyer, M.R., F.T. Peters, and H.H. Maurer, The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos, 2008. 36(11): p. 2345-54.

2007

von Mach, M.A., et al., Comparison of urinary on-site immunoassay screening and gas chromatography-mass spectrometry results of 111 patients with suspected poisoning presenting at an emergency department. Ther Drug Monit, 2007. 29(1): p. 27-39.

Sauer, C., et al., Studies on the CYP isoform dependent metabolism of the new phencyclidine-derived designer drug PCEPA. Therapeutic Drug Monitoring, 2007. 29(4): p. 463-463.

Peters, F.T., et al., Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone. Biochem Pharmacol, 2007. 74(3): p. 511-20.

2005

Peters, F.T., et al., Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2005. 824(1-2): p. 81-91.